3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Paclitaxel
10
pembrolizumab
9
Cyclophosphamide
9
Flow Cytometry
7
sargramostim
6
Therapeutics
6
Taxes
5
Polymerase Chain Reaction
5
Immunoenzyme Techniques
5
Docetaxel
5
Carboplatin
5
aldesleukin
4
Psychiatric Rehabilitation
4
Fulvestrant
4
Filgrastim
4
ribociclib
3
Trastuzumab
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Mass Spectrometry
3
Interleukin-12 Subunit p35
3
Immunologic Techniques
3
Immunohistochemistry
3
Gene Expression Profiling
3
Amplified Fragment Length Polymorphism Analysis
3
Amifostine
3
talazoparib
2
spartalizumab
2
sacituzumab govitecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
bemarituzumab
×
Breast
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled